Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGTC-401 in CNGB3 Achromatopsia
NCT02599922Phase 2Active, not recruiting
- Sponsor
- Beacon Therapeutics
- Start
- Apr 2016
- Primary completion
- Jul 2022
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 2 trial of AGTC-401 in achromatopsia (ACHM), sponsored by Beacon Therapeutics. Started Apr 2016; status: active, not recruiting.
02
Drugs
AGTC-401
03
Conditions
achromatopsia (ACHM)
Beyond the preview
Go deeper on NCT02599922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02599922.